All participants and

their parents gave informed written consent before entering the study. The study was approved by the Research Ethics Committee of Helsinki University Hospital and performed according to the Declaration of Helsinki. The subjects completed a questionnaire on overall health, medical and fracture Alpelisib clinical trial history, medications, age at menarche, use of supplements and details about their physical activity. If necessary, additional information was obtained by interview. Dietary vitamin D and calcium intakes during the previous month were estimated using a food frequency questionnaire (covering over 70 foods), which has been validated against S-25(OH)D and 3-day food records [13], [14] and [15]. The calculations of the food nutrient contents were performed using the Pexidartinib Finnish National Food Composition Database (Fineli®, version 2001, National Institute for Health and Welfare). The recorded physical activity data included regular every-day activities (e.g. walking to school), activity at

school, and both guided and unguided leisure-time activities during two preceding years. The duration, frequency and intensity of activity sessions were evaluated. A total physical activity score was obtained by adding the indices and intensity, as described in detail previously [12]. Heights and weights were measured and compared with Finnish normative data[16] and [17]. In the absence of Finnish normative data, body mass index Z-scores were calculated according to WHO (http://www.who.int). Pubertal development was scored either pre-, mid- or postpubertal based on serum hormone concentrations by a pediatric endocrinologist (OM). Blood samples and second void urine were collected at 8–10 am after an overnight fast. All samples were collected between November and March (wintertime). Plasma calcium (Ca), phosphate (Pi), alkaline phosphatase (ALP) and urinary concentrations of Ca, Pi and creatinine were measured using standard methods. Reference ranges for plasma ALP were age-and sex-dependent and the measured values were transformed into

Z-scores using normal values to allow for cross-sectional comparison. S-25(OH)D was assayed with high-performance liquid chromatography (HPLC, evaluated Vitamin D External Quality Assessment Scheme, DEQAS), and 5-Fluoracil datasheet plasma fasting parathyroid hormone (PTH) by an immunoluminometric method. Total serum intact FGF23 was analyzed by ELISA assay (FGF23 Kit, Kainos laboratories INC., Tokyo, Japan). Bone turnover markers N-terminal propeptide of type I procollagen (PINP) and C-terminal telopeptide of type I collagen (ICTP), reflecting bone formation and resorption, were measured from serum by radioimmunoassay (UniQ, Orion Diagnostica, Espoo, Finland) and results were interpreted in comparison to in-house age-specific reference values and transformed into Z-scores. All blood and urine measurements were analyzed at the Central Laboratory of Helsinki University Central Hospital.